Amarantus Bioscience Holdings Inc (AMBS)

[av1atic]

Amarantus Posts Review of MANF Literature to Web Site

SUNNYVALE, Calif.-- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has posted to its Web site a White Paper titled “A Review of MANF Literature: Implications for the Development Program of Amarantus Bioscience Holdings.” The White Paper can be found at http://ir.stockpr.com/amarantus/scientific-publications.

“This extensive report on our lead therapeutic MANF is valuable to a number of audiences, including life science research professionals, potential development partners, and investors as they conduct due diligence to better understand the breadth of the technology,“ said Amarantus Chief Executive Officer Gerald Commissiong. “It is the most comprehensive discussion of the properties and potential of MANF, and we believe it will significantly enhance understanding of our MANF therapeutic program.”

Prepared by the consulting firm NeuroAssets, the 41-page report covers MANF’s protein structure and cellular activities; studies related to Parkinson’s disease, stroke, myocardial infarction and traumatic brain injury; and the potential for further development of MANF.

http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdf